



Key Inflammatory Processes in Human NASH Are Reflected in $Ldlr^{-/-}$.Leiden Mice: A Translational Gene Profiling Study

Martine C. Morrison¹, Robert Kleemann^{1,2}, Arianne van Koppen¹, Roeland Hanemaaijer¹ and Lars Verschuren^{3*}

¹ Department of Metabolic Health Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands, ² Department of Vascular Surgery, Leiden University Medical Center, Leiden, Netherlands, ³ Department of Microbiology and Systems Biology, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands

OPEN ACCESS

Edited by:

Carlos Rosales,
Universidad Nacional Autónoma de
México, Mexico

Reviewed by:

Ramani Soundararajan,
University of South Florida,
United States
Savneet Kaur,
Institute of Liver and Biliary Sciences,
India

*Correspondence:

Lars Verschuren
lars.verschuren@tno.nl

Specialty section:

This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology

Received: 11 October 2017

Accepted: 08 February 2018

Published: 23 February 2018

Citation:

Morrison MC, Kleemann R, van
Koppen A, Hanemaaijer R and
Verschuren L (2018) Key Inflammatory
Processes in Human NASH Are
Reflected in $Ldlr^{-/-}$.Leiden Mice: A
Translational Gene Profiling Study.
Front. Physiol. 9:132.
doi: 10.3389/fphys.2018.00132

Introduction: It is generally accepted that metabolic inflammation in the liver is an important driver of disease progression in NASH and associated matrix remodeling/fibrosis. However, the exact molecular inflammatory mechanisms are poorly defined in human studies. Investigation of key pathogenic mechanisms requires the use of pre-clinical models, for instance for time-resolved studies. Such models must reflect molecular disease processes of importance in patients. Herein we characterized inflammation in NASH patients on the molecular level by transcriptomics and investigated whether key human disease pathways can be recapitulated experimentally in $Ldlr^{-/-}$.Leiden mice, an established pre-clinical model of NASH.

Methods: Human molecular inflammatory processes were defined using a publicly available NASH gene expression profiling dataset (GSE48452) allowing the comparison of biopsy-confirmed NASH patients with normal controls. Gene profiling data from high-fat diet (HFD)-fed $Ldlr^{-/-}$.Leiden mice (GSE109345) were used for assessment of the translational value of these mice.

Results: In human NASH livers, we observed regulation of 65 canonical pathways of which the majority was involved in inflammation (32%), lipid metabolism (16%), and extracellular matrix/remodeling (12%). A similar distribution of pathways across these categories, inflammation (36%), lipid metabolism (24%) and extracellular matrix/remodeling (8%) was observed in HFD-fed $Ldlr^{-/-}$.Leiden mice. Detailed evaluation of these pathways revealed that a substantial proportion (11 out of 13) of human NASH inflammatory pathways was recapitulated in $Ldlr^{-/-}$.Leiden mice. Furthermore, the activation state of identified master regulators of inflammation (i.e., specific transcription factors, cytokines, and growth factors) in human NASH was largely reflected in $Ldlr^{-/-}$.Leiden mice, further substantiating its translational value.

Conclusion: Human NASH is characterized by upregulation of specific inflammatory processes (e.g., “Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes,” “PI3K signaling in B Lymphocytes”) and master regulators (e.g., TNF, CSF2, TGFB1). The majority of these processes and regulators are modulated in the

same direction in *Ldlr*^{-/-}.Leiden mice fed HFD with a human-like macronutrient composition, thus demonstrating that specific experimental conditions recapitulate human disease on the molecular level of disease pathways and upstream/master regulators.

Keywords: liver, NASH, inflammation, molecular, gene expression, translational, mouse, human

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is one of the most important causes of chronic liver disease worldwide (Wong et al., 2015; Younossi et al., 2017). The prevalence of NAFLD is rising in close association with the increasing prevalence of obesity, insulin resistance, and dyslipidemia, all of which are risk factors for NAFLD (Siddiqui et al., 2015; Chang et al., 2016; Dongiovanni et al., 2016; Katsiki et al., 2016). NAFLD encompasses a spectrum of liver disease: ranging from the relatively benign hepatic steatosis, which is characterized by the accumulation of lipids in the liver, to non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD.

NASH is characterized by the presence of hepatocellular damage and inflammation (Rinella, 2015), which in concert can drive the development of liver fibrosis (Fujii and Kawada, 2012), the strongest predictor of NAFLD-related mortality (Angulo et al., 2015; Ekstedt et al., 2015). The hepatic inflammatory response in NASH is poorly characterized on the molecular level and thought to originate from a combination of various chronic pro-inflammatory triggers (Tilg and Moschen, 2010). In addition to direct lipotoxicity resulting from the build-up of pro-inflammatory lipid species in the liver (such as free fatty acids, diglycerides, ceramides, and free cholesterol) (Alkhoury et al., 2009), the inability of hepatocytes to cope with an increased metabolic load is thought to lead to ER stress, metabolic dysfunction and production of reactive oxygen species, which in turn can contribute to exacerbation of the hepatic inflammatory response (Takaki et al., 2014). On top of that, it is thought that extrahepatic pro-inflammatory signals from the adipose tissue and the gut can drive hepatic inflammation in NASH (Tilg and Moschen, 2010; Takaki et al., 2014).

The exact molecular events in liver that contribute to this chronic inflammatory condition are not well-characterized, and much remains unknown about the nature of these molecular inflammatory processes in NASH. While a number of studies has explored genome-wide hepatic gene expression in NASH patients (Younossi et al., 2005; Zhang et al., 2012; Moylan et al., 2014; Arendt et al., 2015; Teufel et al., 2016) none of these has focused on unraveling the inflammatory response. Since studies based on human liver biopsy material generally do not allow in-depth mechanistic studies or time-resolved investigation of disease progression, pre-clinical disease models are key to the development of a deeper mechanistic understanding of pathogenesis and are required for testing of new therapeutic interventions (Hebbard and George, 2011). To study mechanisms of disease development in pre-clinical models, it is critical that the model employed is reflective of human disease processes.

A wide variety of animal models for NASH is available, each with their own specific advantages and disadvantages (Ibrahim et al., 2016; Jacobs et al., 2016). The translational value of these experimental models is often judged on basis of histopathological features but not on the molecular pathophysiological level, i.e., whether they recapitulate the disease pathways that are evoked in NASH patients. Hence, the translational value of most models is currently under debate, the more so because many models are not sufficiently validated. A recent study compared different animal models with the full spectrum of NAFLD patients using gene profiling and concluded that none of the investigated animal models mimics the complete spectrum of molecular processes involved in humans (Teufel et al., 2016). However, it has been shown that diet-inducible models showed at least some similarities in the development of disease. Therefore this study and other reports (Hebbard and George, 2011; Mulder et al., 2016) suggest that diet-induced models may best reflect sub-processes of human disease phenotypes and underlying pathogenesis.

In the current study we characterized specifically the sub-process of inflammation in human NASH and evaluated the translational value of the high-fat-diet (HFD)-fed *Ldlr*^{-/-}.Leiden mouse with regards to the hepatic inflammatory response in NASH. This NASH model was not included in the comparison of hepatic gene expression in murine and human NASH described above (Teufel et al., 2016). *Ldlr*^{-/-}.Leiden mice display phenotypical and histopathological characteristics of NASH patients when fed a human like-HFD without requiring amino acid and choline deficiency or supraphysiologic levels of cholesterol in the diet (Liang et al., 2014; Morrison et al., 2016; van Koppen et al., 2018). More specifically, they develop NASH in the context of an obese phenotype with hypercholesterolemia, hypertriglyceridemia, and hyperinsulinemia as observed in many patients (Anderson and Borlak, 2008; Loomba and Sanyal, 2013). Histopathologically, these mice show presence of micro- and macrovesicular steatosis in the liver, hepatocellular hypertrophy with hepatocellular disintegration and sporadic ballooning, lobular inflammation (mixed-cell inflammatory infiltrates) and marked hepatic fibrosis that progresses with prolonged HFD treatment. In a recent comparison of NASH-induced regulation of hepatic gene expression (using an unbiased approach), HFD-fed *Ldlr*^{-/-}.Leiden mice were found to recapitulate many of the gene expression changes observed in human NASH (van Koppen et al., 2018). The current study focuses specifically on the inflammatory component of NASH, first defining the main molecular inflammatory processes present in human NASH using available published information and subsequently exploring the representation of these processes in HFD-fed *Ldlr*^{-/-}.Leiden mice.

MATERIALS AND METHODS

Human Hepatic Gene Expression Dataset

For the investigation of molecular inflammatory processes in human NASH, samples were selected from a published dataset accessible at the NCBI Gene Expression Omnibus (GEO) database, accession GSE48452. This dataset originates from a study on DNA methylation patterns in NASH patients (Ahrens et al., 2013) that included morbidly obese patients with biopsy-confirmed NAFLD pre- and post-bariatric surgery, as well as healthy controls. In this study, gene expression levels were measured using Affymetrix Human Gene 1.1 ST array (Affymetrix Inc., Santa Clara, California, USA). For the purpose of the present study, we selected the pre-bariatric surgery samples from NASH patients ($n = 17$) and compared them with the healthy controls ($n = 12$) (see sample list in Supplemental Table 1). The probe-level, background-subtracted, expression values were used as input for lumi package (Du et al., 2008) of the R/Bioconductor (<http://www.bioconductor.org>; <http://www.r-project.org>) to perform quality control and quantile normalization. Differentially expressed probes were identified using the limma package of R/Bioconductor (Wettenhall and Smyth, 2004), calculated values of $P < 0.01$ were used as threshold for significance.

Murine Hepatic Gene Expression Dataset

Murine gene expression data was obtained from a previously published study (van Koppen et al., 2018) and the dataset is accessible at the NCBI GEO database via accession number GSE109345. Detailed methods of tissue collection and processing as well as next generation sequencing (NGS) and statistical analysis are described in van Koppen et al. (2018). Briefly, $n = 15$ Ldlr^{-/-}.Leiden mice (94% C57BL/6J background, 6% 129S1/SvImJ background) were fed an energy-dense high-fat diet (HFD; 45 kcal% fat from lard, 17 kcal% sucrose) for 24 weeks to induce NASH (steatosis, inflammation, early fibrosis) in the context of obesity, hyperlipidemia and hyperinsulinemia. Hepatic gene expression dataset of HFD-treated mice was generated and data were expressed relative to age-matched chow-fed controls ($n = 15$).

Data- and Statistical Analysis

Differentially expressed probes (from human dataset) and counts (from mouse dataset) confined with the statistical cut-off were used as input for pathway analysis through Ingenuity Pathway Analysis (IPA) suite (www.ingenuity.com, accessed 2017) as described previously (Morrison et al., 2015; Mulder et al., 2016; van Koppen et al., 2018). An upstream regulator analysis, which is part of IPA, predicts the activation state of a protein, enzyme or transcription factor based on the expression pattern of the genes downstream of this factor. The z-score indicates the predicted activation state of a transcription factor or key regulator: $z \leq -2$ indicates relevant inhibition (shown in green), $z \geq 2$ indicates relevant activation (shown in red). Pathway-based overlap analysis was performed by using Venny 2.1 (Oliveros, 2007) and heatmaps were generated using a web-based tool (Babicki et al., 2016).

The genes that belong to significantly regulated inflammatory canonical pathways were visualized using Neo4J (Neo4j, Inc, San Mateo, CA, USA) a graph database with query-based calculations.

RESULTS


Key Inflammatory Processes and Regulators in NASH Liver Biopsies

To define the major inflammatory processes that are modulated during NASH development, gene expression profiles in liver biopsies from NASH patients were compared to those of healthy control livers using a published human dataset (GSE48452). In total 12 healthy controls and 17 patients with biopsy-proven NASH were analyzed. At a statistical cut-off of $P < 0.01$, 972 genes were differentially expressed between the two groups, i.e., 519 genes were upregulated and 453 genes were downregulated in NASH livers relative to healthy controls. All these NASH-associated genes were used as input for pathway analysis, which integrates the expression of a multitude of genes in pre-defined biological and disease-associated pathways thus allowing summation of multiple (small) gene expression changes to provide information on the effect on entire pathways rather than single genes.

The top 20 most significantly enriched pathways are visualized in **Figure 1A**; this top 20 includes canonical pathways involved in various (patho)physiological processes such as lipid metabolism, inflammation and hepatic fibrosis. When taking all significantly enriched canonical pathways [$-\log(P\text{-value}) > 2$] into account, the majority of pathways appear to be related to inflammation (32%) while other pathways are related to lipid metabolism (16%) or extracellular matrix remodeling (12%; **Figure 1B**).

A total of 13 pathways was related to inflammation, among which “Fc γ Receptor-mediated Phagocytosis in Macrophages and Monocytes,” “PI3K signaling in B Lymphocytes” and “Leukocyte Extravasation Signaling” (**Figure 2A**). Subsequent refined analysis of the genes that are part of these pathways showed that the expression of the majority of the individual genes is significantly upregulated in NASH patients relative to controls. The consistency of this upregulation is exemplified for the pathway “Leukocyte Extravasation Signaling” (**Figure 2B**).

We subsequently analyzed inflammatory processes in NASH in more detail by performing an upstream regulator analysis. This analysis predicts the activation state (indicated by a positive/negative z-score for activation/inhibition) of upstream regulators (e.g., transcription factors and cytokines) in NASH livers relative to healthy controls. **Table 1** shows the inflammation-related upstream regulators that were significantly activated (in red) or inhibited (in green) in NASH patients. We observed an activation of classical regulators of inflammation such as the cytokines TNF (Tumor necrosis factor alpha), CSF2 (Granulocyte-macrophage colony-stimulating factor) and TGF β 1 (Transforming growth factor beta 1) as well as factors that can indirectly affect inflammatory processes, such as ESR2 (Estrogen receptor 2), and PLG (Plasminogen). In addition, a known inhibitor of inflammation AHR (Aryl hydrocarbon



receptor) (Li et al., 2011) was predicted to be inactive in NASH relative to healthy controls.

Key Inflammatory Processes and Regulators in Murine NASH Development

To investigate whether similar inflammatory processes were evoked in murine NASH, we studied hepatic gene expression profiles of HFD-fed *Ldlr*^{-/-}.Leiden mice, which display

phenotypical and histopathological characteristics of NASH patients (Liang et al., 2014; Morrison et al., 2016). We compared hepatic gene expression profiles of 24-week HFD-fed mice (at the stage of hepatic steatosis, inflammation and early fibrosis) to those of age-matched healthy controls (chow-fed *Ldlr*^{-/-}.Leiden mice) using data from a recently published study (van Koppen et al., 2018, GSE 109345). In total, 2,680 genes were differentially expressed between the two groups (1,639 upregulated, 1,046




FIGURE 2 | Enrichment analysis of inflammatory pathways in NASH patients. **(A)** Visualization of all inflammation-related canonical pathways in human NASH patients as compared to normal controls. Values are expressed as $-\log(p\text{-value})$. **(B)** Visualization of the expression change in NASH patients as compared to normal controls for the canonical pathway “Leukocyte Extravasation Signaling.” Red color indicates significant upregulated genes and green color indicates significant downregulated genes.

downregulated; $P < 0.001$). Subsequent pathway analysis revealed that, as seen in human NASH, the majority of regulated pathways is related to inflammation (36%) while many of the other most significantly regulated pathways are involved in lipid metabolism (24%) and extracellular matrix remodeling (8%) (**Figure 3A**). A total of 27 pathways were related to inflammation, for instance “Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes,” “IL-8 signaling,” “Production of Nitric Oxide and Reactive Oxygen Species in Macrophages” and “Leukocyte Extravasation Signaling” (**Figure 3B**). As observed in human NASH, the expression of most of the individual genes

that make up these inflammatory pathways were upregulated in HFD-fed mice relative to healthy controls, as is illustrated for the “Leukocyte Extravasation Signaling” pathway (**Figure 3C**). To determine which inflammation-related upstream regulators are involved in the development of murine NASH, an upstream regulator analysis was performed to identify significantly activated or inhibited regulators in HFD-fed $Ldlr^{-/-}$. Leiden mice relative to their age-matched healthy controls (shown in **Table 2**). This analysis revealed significant activation of many classical chemokines (e.g., CCL2, CCL5, CXCL2, CXCL3), cytokines (e.g., TNF, TGFβ1, IL1β, CSF2) and transcriptional

TABLE 1 | Significantly modulated inflammation-related upstream regulators in human NASH vs. control.

| Upstream regulator | NASH vs. CTRL | |
|--------------------|--------------------|-----------|
| | Activation z-score | p-value |
| TNF | 2.426 | 0.0000011 |
| CEBPA | 2.149 | 0.0000251 |
| CSF2 | 3.144 | 0.0000448 |
| IGF1 | 3.918 | 0.000118 |
| SP1 | 3.14 | 0.000154 |
| IL5 | 1.86 | 0.000213 |
| DSP | -2.219 | 0.000327 |
| TGM2 | 2.18 | 0.000372 |
| ERG | 3.035 | 0.000386 |
| TGFB1 | 2.64 | 0.00051 |
| ERBB2 | 3.393 | 0.00064 |
| SREBF2 | 3.115 | 0.000703 |
| PARP2 | 1.987 | 0.000706 |
| ATP7B | 2.646 | 0.000872 |
| MLXIPL | 2.198 | 0.00113 |
| RUNX3 | -1.982 | 0.00125 |
| SNAI1 | 2.219 | 0.00183 |
| ESR2 | 2.316 | 0.00254 |
| EGR1 | 2.381 | 0.00264 |
| CREBBP | 2.266 | 0.00265 |
| PLG | 2.121 | 0.00298 |
| FGF2 | 2.203 | 0.00317 |
| ETS2 | 2.158 | 0.0051 |
| AHR | -3.035 | 0.00528 |
| RHOA | 2.63 | 0.00694 |
| TET2 | 2.111 | 0.00708 |
| GLI1 | 2.072 | 0.00841 |

The z-score indicates the predicted activation state of a transcription factor or key regulator: $z \leq -2$ indicates relevant inhibition (shown in green), $z \geq 2$ indicates relevant activation (shown in red). The p-value indicates significant enrichment of the genes downstream of a regulator ($p < 0.01$ was considered statistically significant).

regulators of inflammation (e.g., NF-KB, STAT4, JUN) as well as factors with indirect links to inflammation (e.g., FGF2, FOXO1, PLG). Several anti-inflammatory factors were found to be significantly inactivated in NASH livers including AHR and others (e.g., IL10RA, IL1RN) which is consistent with the observations in humans.

Overlap in Inflammatory Processes between Human and Experimental NASH

Next, we investigated in more detail whether these NASH-associated molecular inflammatory processes are similar in human and murine NASH, and to what extent the individual genes are similarly regulated. To evaluate the overlap of canonical inflammatory pathways between human and murine NASH, pathways were integrated using an overlay Venn-diagram. Thirteen inflammatory pathways were significantly regulated in human NASH and 27 inflammatory pathways were significantly regulated in murine NASH. Interestingly, a large

part—11 out of 13 pathways—of the human inflammatory processes were also regulated in HFD-fed *Ldlr*^{-/-}.Leiden mice (Figure 4A), including several macrophage-related pathways such as “Production of Nitric Oxide and Reactive Oxygen Species in Macrophages,” “Macropinocytosis Signaling,” and “Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes” but also pathways related to other inflammatory cell types, such as “Dendritic Cell Maturation,” “B Cell Receptor Signaling,” and “Natural Killer Cell Signaling” (Table 3). Next, we investigated the differentially expressed genes underlying the shared pathways in human NASH and identified which of these were also regulated in the HFD-fed *Ldlr*^{-/-}.Leiden mouse (Figure 4B). We then evaluated the conformity in direction of these genes that were differentially regulated in both human and murine NASH (i.e., upregulation or downregulation relative to control) (Figure 4C) and found that 83% of the shared genes (in either human or murine NASH) changed in the same direction in human and mouse NASH.

Finally, we investigated the overlap of upstream regulators between human and mouse NASH using an overlay Venn-diagram (Figure 5A). A total of 25 inflammation-related upstream regulators was significantly regulated in human NASH, and 76 inflammation-related upstream regulators were significantly regulated in HFD-fed mice. Of the 25 inflammation-related factors that were regulated in human NASH, 18 were also affected in HFD-fed *Ldlr*^{-/-}.Leiden mice, including the pathways downstream of the cytokines TNF, TGFB1 and CSF2 which were activated in both human and murine NASH. Analysis of the direction of regulation, i.e., predicted activation or predicted inhibition of the upstream regulator, showed that the majority of the overlapping upstream regulators was regulated in the same direction in *Ldlr*^{-/-}.Leiden mice as in NASH patients (Figure 5B) supporting the translational value of the experimental model conditions.

DISCUSSION

This study defines the major molecular inflammatory pathways and key regulators in human NASH using gene profiling data from liver biopsies, and provides evidence that the major molecular responses in humans can be replicated experimentally in a diet-inducible NASH model, the HFD-fed *Ldlr*^{-/-}.Leiden mouse.

Studies on human gene expression in NASH are scarce, typically include only a small number of patients, and datasets are not always made publicly available (Moylan et al., 2014; Arendt et al., 2015; Teufel et al., 2016; Lefebvre et al., 2017). Typically, the patients used therein are drawn from a patient population with known heterogeneity (Machado and Diehl, 2016; Younossi et al., 2016) for instance due to variations in disease etiology, ethnicity, gender, lifestyle and dietary habits. Herein we used an open access gene profiling dataset (Ahrens et al., 2013; Teufel et al., 2016) and, despite these limitations, such as a limited number of samples, were able to identify a number of significantly regulated inflammatory pathways and upstream regulators, indicating that these may be key inflammatory processes that




FIGURE 3 | Enrichment analysis of molecular pathways in HFD-fed *Ldlr^{-/-}*.Leiden mice. **(A)** Circle chart which classifies canonical pathways into more general biological processes and illustrates the proportion of pathways in each of these categories. **(B)** Visualization of all inflammation-related canonical pathways in HFD-fed *Ldlr^{-/-}*.Leiden mice. **(C)** Visualization of the expression change in HFD-fed *Ldlr^{-/-}*.Leiden mice as compared to chow controls for the canonical pathway “Leukocyte Extravasation Signaling.” Red color indicates significant upregulated genes and green color indicates significant downregulated genes.

TABLE 2 | Significantly modulated inflammation-related upstream regulators in HFD-fed Ldlr^{-/-}.Leiden mice vs. chow.

| HFD vs. Chow | | |
|--------------------|--------------------|----------|
| Upstream regulator | Activation z-score | p-value |
| TGFB1 | 7.849 | 1.96E-57 |
| TNF | 9.244 | 6.44E-52 |
| IFNG | 8.757 | 3.3E-47 |
| TP53 | 2.363 | 9.73E-42 |
| IL1B | 7.97 | 4.03E-34 |
| ERBB2 | 2.374 | 1.38E-32 |
| IL6 | 4.47 | 1.68E-32 |
| IL13 | 3.514 | 3.49E-30 |
| IL10RA | -3.494 | 2.83E-26 |
| IL4 | 3.087 | 3.12E-26 |
| AHR | -3.408 | 1.99E-25 |
| NFKBIA | 3.976 | 3.41E-22 |
| SP1 | 3.337 | 3.99E-22 |
| STAT3 | 2.572 | 5.1E-22 |
| CSF2 | 6.882 | 3.02E-21 |
| IL2 | 5.83 | 1.65E-18 |
| JUN | 3.138 | 3.34E-18 |
| SREBF2 | -4.082 | 5.14E-18 |
| IKBKB | 4.584 | 4.38E-17 |
| STAT1 | 6.505 | 5.96E-17 |
| IFNB1 | 3.99 | 6.31E-17 |
| CSF1 | 4.48 | 1.59E-16 |
| CSF3 | 2.881 | 9.27E-16 |
| CD44 | 5.442 | 9.32E-16 |
| CEBPB | 2.814 | 5.24E-15 |
| TGM2 | 5.805 | 1.16E-14 |
| IL1 | 5.181 | 1.66E-14 |
| EGF | 4.346 | 4.27E-14 |
| IL5 | 4.57 | 4.3E-14 |
| MYD88 | 6.236 | 4.42E-14 |
| TLR4 | 6.077 | 9.01E-14 |
| IL17A | 4.377 | 3.69E-13 |
| IKBKG | 4.505 | 5.84E-13 |
| IL3 | 3.661 | 1.73E-12 |
| IGF1 | 3.725 | 7.38E-12 |
| IL1A | 5.712 | 1.55E-11 |
| CREBBP | 2.868 | 3.2E-11 |
| STAT4 | 4.14 | 3.74E-11 |
| TLR3 | 5.923 | 4.1E-11 |
| FOXO1 | 3.171 | 4.13E-11 |
| TLR9 | 5.532 | 4.79E-11 |
| FGF2 | 3.295 | 8.43E-11 |
| HGF | 3.624 | 1.64E-10 |
| EGR1 | 3.58 | 2.35E-10 |
| CCL5 | 2.583 | 4.74E-10 |
| NFKB1 | 4.307 | 6.73E-10 |
| SMAD3 | 4.858 | 2.92E-09 |
| RELA | 4.325 | 4.43E-09 |


(Continued)

TABLE 2 | Continued

| HFD vs. Chow | | |
|--------------------|--------------------|----------|
| Upstream regulator | Activation z-score | p-value |
| ATP7B | -3.771 | 4.66E-09 |
| CXCL12 | 4.638 | 1.09E-08 |
| IL15 | 3.372 | 1.72E-08 |
| JUNB | 2.91 | 5.15E-08 |
| SPDEF | -3.725 | 5.64E-08 |
| TNFSF12 | 4.161 | 7.22E-08 |
| FGFR2 | 2.368 | 1.05E-07 |
| TGFA | 2.134 | 2.15E-07 |
| LIF | 2.452 | 4.86E-07 |
| IL1RN | -4.697 | 7.80E-07 |
| IL18 | 5.15 | 8.27E-07 |
| IL21 | 3.514 | 1.84E-06 |
| CCL2 | 2.23 | 2.04E-06 |
| ERG | 5.112 | 2.09E-06 |
| CXCL3 | 3.109 | 3.39E-06 |
| CXCL2 | 3.057 | 3.39E-06 |
| Ccl2 | 2.497 | 4.70E-06 |
| WNT3A | 2.287 | 4.90E-06 |
| PLG | 4.065 | 5.59E-06 |
| TET2 | 2.828 | 6.97E-06 |
| KLF4 | 3.272 | 9.16E-06 |
| IL27 | 4.527 | 1.10E-05 |
| CEBPD | 2.434 | 1.21E-05 |
| MIF | 4.191 | 1.32E-05 |
| TLR7 | 5.145 | 1.35E-05 |
| SMAD1 | 2.3 | 4.74E-05 |
| GLI1 | 2.211 | 1.02E-04 |
| FOXA3 | -2.093 | 1.06E-04 |

The z-score indicates the predicted activation state of a transcription factor or key regulator: $z \leq -2$ indicates relevant inhibition (shown in green), $z \geq 2$ indicates relevant activation (shown in red). The p-value indicates significant enrichment of the genes downstream of a regulator ($p < 0.001$ was considered statistically significant).

are common in many NASH patients. Many of the identified pathways describe processes to do with inflammatory cells, such as “Leukocyte Extravasation Signaling” and “Chemokine Signaling” which are required for the infiltration of immune cells into the liver, one of the diagnostic criteria for NASH (Kleiner et al., 2005). Several were related to the activity of macrophages (e.g., “Production of Nitric Oxide and Reactive Oxygen Species in Macrophages,” “Macropinocytosis Signaling,” and “Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes”), a cell type that is believed to play an important role in the inflammatory response in NASH (Itoh et al., 2013; Alisi et al., 2017) and is thus considered a promising target for treatment (Tacke, 2017). Immune cell infiltration in general, and macrophage responses in specific, can be the result of various pro-inflammatory stimuli (for instance cholesterol or gut-derived LPS; Heymann and Tacke, 2016), and may therefore represent a downstream phenomenon in NASH that can be the result of various disease-inducing pathways, providing a potential



explanation for its involvement across the heterogeneous patient population.

To provide meaningful information on disease development, disease mechanisms, or effects of new therapeutic interventions, it is critical that a pre-clinical model not only reflects histopathological features of human disease, but also recapitulates human (patho)physiological processes on the molecular level. We found that the vast majority of inflammatory pathways and upstream regulators that were significantly modulated in human NASH were also significantly modulated in the *Ldlr*^{-/-}.Leiden mouse (11 out of 13 pathways and 18 out of 25 upstream regulators), indicating that this model recapitulates the key inflammatory processes of human NASH.

Inbred mouse strains such as the *Ldlr*^{-/-}.Leiden mouse are genetically homogenous and allow study of NASH development under standardized experimental conditions as reported (Morrison et al., 2016; Schoemaker et al., 2017). Furthermore, mice liver samples are collected at a relatively uniform stage of disease development depending on the time of high-caloric diet feeding (Liang et al., 2014; Arnoldussen et al., 2017), while human samples show more varying histopathology within a disease stage. In reflection of this high degree of homogeneity, substantially more genes were differentially expressed relative to healthy control in the *Ldlr*^{-/-}.Leiden mice than in the human samples, and we also found a larger number of pathways and upstream regulators significantly modulated in mice (with a


TABLE 3 | Overlap analysis of significantly regulated pathways in human and murine NASH.

| No. | Canonical Pathway | Human NASH vs. CTRL | Ldlr ^{-/-} .Leiden mouse HFD vs. chow |
|--|---|------------------------|--|
| | | -log(p-value) | -log(p-value) |
| PATHWAYS REGULATED BOTH IN HUMAN NASH AND MURINE NASH | | | |
| 1 | Fcγ Receptor-mediated phagocytosis in macrophages and monocytes | 5.44 | 12.5 |
| 2 | PI3K signaling in B lymphocytes | 3.77 | 7.2 |
| 3 | Leukocyte extravasation signaling | 3.56 | 6.29 |
| 4 | IL-8 signaling | 3.05 | 9.48 |
| 5 | Natural killer cell signaling | 2.95 | 5.82 |
| 6 | Macropinocytosis signaling | 2.87 | 4.78 |
| 7 | B Cell receptor signaling | 2.54 | 4.89 |
| 8 | Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis | 2.53 | 5.74 |
| 9 | Production of nitric oxide and reactive oxygen species in macrophages | 2.36 | 7.98 |
| 10 | Dendritic cell maturation | 2.05 | 6.5 |
| 11 | iCOS-iCOSL signaling in T helper cells | 2.04 | 5.35 |
| PATHWAYS REGULATED ONLY IN MURINE NASH | | | |
| 1 | CD28 signaling in T helper cells | 1.82 | 5.51 |
| 2 | Crosstalk between dendritic cells and natural killer cells | 1.61 | 4.05 |
| 3 | T cell receptor signaling | 1.53 | 3.02 |
| 4 | Acute phase response signaling | 1.43 | 6.84 |
| 5 | PKCθ signaling in T lymphocytes | 1.43 | 4.58 |
| 6 | IL-10 signaling | 1.28 | 4.56 |
| 7 | IL-12 signaling and production in macrophages | 1.18 | 4.02 |
| 8 | LPS/IL-1 mediated inhibition of RXR function | 0.981 | 7.85 |
| 9 | Altered T cell and B cell signaling in rheumatoid arthritis | 0.833 | 5.41 |
| 10 | Th1 and Th2 activation pathway | 0.505 | 4.19 |
| 11 | NF-κB signaling | 0.375 | 5.21 |
| 12 | Th2 pathway | 0.26 | 3.11 |
| 13 | T helper cell differentiation | 0.254 | 3.57 |
| 14 | Toll-like receptor signaling | 0.247 | 6.11 |
| 15 | Inflammasome pathway | 0.242 | 3.42 |
| 16 | Th1 Pathway | N/A | 3.98 |
| PATHWAYS REGULATED ONLY IN HUMAN NASH | | | |
| 1 | Chemokine signaling | 2.16 | 2.44 |
| 2 | LPS-stimulated MAPK signaling | 2.16 | 2.99 |

Significance of enrichment for canonical pathways is indicated by $-\log(p\text{-value})$.

higher level of significance). For instance, we observed regulation of several T-cell related pathways in HFD-fed Ldlr^{-/-}.Leiden mice that were not significantly regulated in the human NASH samples (e.g., “Th1 and Th2 Activation Pathway,” “T Helper Cell Differentiation,” “T Cell Receptor Signaling”). Although much remains unknown about the role of T cells in the development and progression of NASH, alterations in this immune cell population have been reported for NASH patients (Inzaugarat et al., 2011), specifically in more advanced disease stages (i.e., fibrosis score >F2; Gadd et al., 2014). The lack of regulation of T cell-related pathways observed in the current study may be

reflective of the relatively low presence of fibrosis in this patient cohort (mostly F1). In general, pathways that were found to be significantly enriched in mice but not in patients may constitute pathways that are more variably enriched in human disease (e.g., in a subset of NASH patients but not in others—resulting in an average expression level that does not pass the threshold for enrichment). Conversely, there were 2 pathways that were regulated in human NASH but not in the Ldlr^{-/-}.Leiden mouse; “LPS-stimulated MAPK Signaling” and “Chemokine Signaling.” In both pathways it is specifically the MAPK expression which is distinctive in human compared to mouse liver tissue. Since mice



are housed under pathogen-free conditions (SPF) it is amenable that activation of MAPK by LPS is more likely to be observed in the human situation.

Besides phenotypically readily apparent subtypes of NASH patients, such as lean vs. obese patients (Kumar and Mohan, 2017) or diabetic vs. non-diabetic patients (Puchakayala et al., 2015), recent efforts on subtyping NAFLD/NASH patients on the basis of their serum metabolome (Alonso et al., 2017; Iruarrizaga-Lejarreta et al., 2017) have revealed that patients may also be classified on the basis of their molecular disease patterns and have provided insight into molecular pathways that may be impaired in some but not other patients (i.e., synthesis of S-adenosylmethionine). A similar analysis in the *Ldlr*^{-/-}.Leiden mouse revealed that on the metabolome level this model reflects a substantial proportion of NAFLD/NASH patients (Morrison et al., 2017) but the underlying disease mechanisms remain unclear. Further exploration on the gene expression level may shine light on different disease etiologies and the molecular pathways involved in various disease-inducing mechanisms, as well as their divergent representation in the NASH patient population. However, such studies require large cross-sectional gene expression datasets of well-characterized and uniformly graded biopsies of different stages that allow classification of patients into molecular subtypes.

Given this large diversity of disease-inducing mechanisms in human NASH, it is unlikely that one single preclinical

model for NASH will reflect the entire spectrum of underlying molecular responses observed in patients. However, individual models may recapitulate specific aspects of the spectrum of molecular responses seen in humans and can be of value to study that particular mechanism (Morrison et al., 2015; Iruarrizaga-Lejarreta et al., 2017; Zimmer et al., 2017). At the same time, one must always be aware of the limitations of the model employed. The *Ldlr*^{-/-}.Leiden model for instance, while mimicking many aspects of human NASH (e.g., pathophysiology, histology, underlying molecular processes; Liang et al., 2014; Morrison et al., 2016; Mulder et al., 2016; van Koppen et al., 2018), is unsuitable to study interventions that require a functioning LDL receptor (Zimmer et al., 2017). Although many different (diet-inducible) experimental models of NASH have been reported (reviewed elsewhere Takahashi et al., 2012), the vast majority of these models has only been characterized on the pathophysiological and histological level and thus their value in the study of human disease processes remains unclear and requires further investigation.

Altogether, this study defines, to our knowledge for the first time, the key molecular inflammatory responses in biopsies of NASH patients and demonstrates that these are reflected in HFD-fed *Ldlr*^{-/-}.Leiden mice. Comparative gene profiling approaches may help to better estimate the translational value of preclinical models for the NASH population in general, or specific subgroups of NASH patients in particular. Models

that are validated on the molecular level against human disease pathways and key regulators of inflammation, constitute important tools to evaluate new therapeutics that target these pathways.

AUTHOR CONTRIBUTIONS

MM, RK, AvK, RH, and LV: Study concept and design; MM, and LV: Writing the manuscript; MM, and LV: Analysis and interpretation of data; MM, RK, AvK, RH, and LV: Critical revision of manuscript.

REFERENCES

- Ahrens, M., Ammerpohl, O., von Schönfels, W., Kolarova, J., Bens, S., Itzel, T., et al. (2013). DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. *Cell Metab.* 18, 296–302. doi: 10.1016/j.cmet.2013.07.004
- Alisi, A., Carpino, G., Oliveira, F. L., Panera, N., Nobili, V., and Gaudio, E. (2017). The role of tissue macrophage-mediated inflammation on nafld pathogenesis and its clinical implications. *Med. Inflamm.* 2017:8162421. doi: 10.1155/2017/8162421
- Alkhoury, N., Dixon, L. J., and Feldstein, A. E. (2009). Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. *Exp. Rev. Gastroenterol. Hepatol.* 3, 445–451. doi: 10.1586/egh.09.32
- Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., et al. (2017). Metabolomic identification of subtypes of nonalcoholic steatohepatitis. *Gastroenterology* 152, 1449–1461.e7. doi: 10.1053/j.gastro.2017.01.015
- Anderson, N., and Borlak, J. (2008). Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. *Pharmacol. Rev.* 60, 311–357. doi: 10.1124/pr.108.00001
- Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwithaya, P., et al. (2015). Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 149, 389–97.e10. doi: 10.1053/j.gastro.2015.04.043
- Arendt, B. M., Comelli, E. M., Ma, D. W., Lou, W., Teterina, A., Kim, T., et al. (2015). Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. *Hepatology* 61, 1565–1578. doi: 10.1002/hep.27695
- Arnoldussen, I. A. C., Wiesmann, M., Pelgrim, C. E., Wielemaker, E. M., van Duyvenvoorde, W., Amaral-Santos, P. L., et al. (2017). Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice. *Int. J. Obes.* 41, 935–944. doi: 10.1038/ijo.2017.52
- Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J. R., Maciejewski, A., et al. (2016). Heatmapper: web-enabled heat mapping for all. *Nucleic Acids Res.* 44, W147–W153. doi: 10.1093/nar/gkw419
- Chang, Y., Jung, H.-S., Cho, J., Zhang, Y., Yun, K. E., Lazo, M., et al. (2016). Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. *Am. J. Gastroenterol.* 111, 1133–1140. doi: 10.1038/ajg.2016.178
- Dongiovanni, P., Rametta, R., Meroni, M., and Valenti, L. (2016). The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target? *Exp. Rev. Gastroenterol. Hepatol.* 10, 229–242. doi: 10.1586/17474124.2016.1110018
- Du, P., Kibbe, W. A., and Lin, S. M. (2008). lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 24, 1547–1548. doi: 10.1093/bioinformatics/btn224
- Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., et al. (2015). Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 61, 1547–1554. doi: 10.1002/hep.27368
- Fujii, H., and Kawada, N. (2012). Inflammation and fibrogenesis in steatohepatitis. *J. Gastroenterol.* 47, 215–225. doi: 10.1007/s00535-012-0527-x
- Gadd, V. L., Skoien, R., Powell, E. E., Fagan, K. J., Winterford, C., Horsfall, L., et al. (2014). The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. *Hepatology* 59, 1393–1405. doi: 10.1002/hep.26937
- Hebbard, L., and George, J. (2011). Animal models of nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol. Hepatol.* 8, 35–44. doi: 10.1038/nrgastro.2010.191
- Heymann, F., and Tacke, F. (2016). Immunology in the liver - from homeostasis to disease. *Nat. Rev. Gastroenterol. Hepatol.* 13, 88–110. doi: 10.1038/nrgastro.2015.200
- Ibrahim, S. H., Hirsova, P., Malhi, H., and Gores, G. J. (2016). Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame. *Digest. Dis. Sci.* 61, 1325–1336. doi: 10.1007/s10620-015-3977-1
- Inzaugarat, M. E., Ferreyra Solari, N. E., Billordo, L. A., Abecasis, R., Gadano, A. C., and Chernaevsky, A. C. (2011). Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. *J. Clin. Immunol.* 31, 1120–1130. doi: 10.1007/s10875-011-9571-1
- Iruarizaga-Lejarreta, M., Varela-Rey, M., Fernández-Ramos, D., Martínez-Arranz, I., Delgado, T. C., Simon, J., et al. (2017). Role of aramchol in steatohepatitis and fibrosis in mice. *Hepatol. Commun.* 1, 911–927. doi: 10.1002/hep4.1107
- Itoh, M., Kato, H., Suganami, T., Konuma, K., Marumoto, Y., Terai, S., et al. (2013). Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. *PLoS ONE* 8:e82163. doi: 10.1371/journal.pone.0082163
- Jacobs, A., Warda, A.-S., Verbeek, J., Cassiman, D. and Spincemaille, P. (2016). An overview of mouse models of nonalcoholic steatohepatitis: from past to present. *Curr. Protoc. Mouse Biol.* 6, 185–200. doi: 10.1002/cpmo.3
- Katsiki, N., Mikhailidis, D. P., and Mantzoros, C. S. (2016). Non-alcoholic fatty liver disease and dyslipidemia: an update. *Metabolism* 65, 1109–1123. doi: 10.1016/j.metabol.2016.05.003
- Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 41, 1313–1321. doi: 10.1002/hep.20701
- Kumar, R., and Mohan, S. (2017). Non-alcoholic fatty liver disease in lean subjects: characteristics and implications. *J. Clin. Trans. Hepatol.* 5, 216–223. doi: 10.14218/JCTH.2016.00068
- Lefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., et al. (2017). Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPAR α -regulated dermatopontin. *JCI Insight* 2:92264. doi: 10.1172/jci.insight.92264
- Li, Y., Innocentin, S., Withers David, R., Roberts Natalie, A., Gallagher Alec, R., Grigorieva Elena, F., et al. (2011). Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. *Cell* 147, 629–640. doi: 10.1016/j.cell.2011.09.025
- Liang, W., Menke, A. L., Driessen, A., Koek, G. H., Lindeman, J. H., Stoop, R., et al. (2014). Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. *PLoS ONE* 9:e115922. doi: 10.1371/journal.pone.0115922

FUNDING

The work was funded by the TNO research program “Predictive Health Technologies” and supported by a grant from ZonMW (grant#114025001).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphys.2018.00132/full#supplementary-material>

- Loomba, R., and Sanyal, A. J. (2013). The global NAFLD epidemic. *Nat. Rev. Gastroenterol. Hepatol.* 10, 686–690. doi: 10.1038/nrgastro.2013.171
- Machado, M. V., and Diehl, A. M. (2016). Pathogenesis of nonalcoholic steatohepatitis. *Gastroenterology* 150, 1769–1777. doi: 10.1053/j.gastro.2016.02.066
- Morrison, M. C., Liang, W., Mulder, P., Verschuren, L., Pieterman, E., Toet, K., et al. (2015). Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE*3Leiden mice. *J. Hepatol.* 62, 1180–1186. doi: 10.1016/j.jhep.2014.12.011
- Morrison, M. C., Mulder, P., Salic, K., Verheij, J., Liang, W., van Duyvenvoorde, W., et al. (2016). Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in Ldlr^{-/-}.Leiden mice. *Int. J. Obesity* 40, 1416–1423. doi: 10.1038/ijo.2016.74
- Morrison, M. C., Verschuren, L., Salic, K., Menke, A., Verheij, J., Iruarizaga-Lejarreta, M., et al. (2017). “Application of human NASH-based transcriptome and metabolome profiles in preclinical models for the translational study of drug effects on liver fibrosis,” in *AASLD Liver Meeting, Abstract ID 253: Hepatology* (Washington, DC).
- Moylan, C. A., Pang, H., Dellinger, A., Suzuki, A., Garrett, M. E., Guy, C. D., et al. (2014). Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. *Hepatology* 59, 471–482. doi: 10.1002/hep.26661
- Mulder, P., Morrison, M. C., Verschuren, L., Liang, W., van Bockel, J. H., Kooistra, T., et al. (2016). Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice. *Sci. Rep.* 6:31542. doi: 10.1038/srep31542
- Oliveros, J. C. (2007). VENN. *An Interactive Tool for Comparing Lists with Venn Diagrams*. Available online at: <http://bioinfogp.cnb.csic.es/tools/venny/index.html> (Cited 2017).
- Puchakayala, B. K., Verma, S., Kanwar, P., Hart, J., Sanivarapu, R. R., and Mohanty, S. R. (2015). Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. *World J. Hepatol.* 7, 2610–2618. doi: 10.4254/wjh.v7.i25.2610
- Rinella, M. E. (2015). Nonalcoholic fatty liver disease: a systematic review. *J. Am. Med. Assoc.* 313, 2263–2273. doi: 10.1001/jama.2015.5370
- Schoemaker, M. H., Kleemann, R., Morrison, M. C., Verheij, J., Salic, K., van Tol, E. A. F., et al. (2017). A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr^{-/-}.Leiden mice. *PLOS ONE* 12:e0180648. doi: 10.1371/journal.pone.0180648
- Siddiqui, M. S., Fuchs, M., Idowu, M. O., Luketic, V. A., Boyett, S., Sargeant, C., et al. (2015). Severity of Nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. *Clin. Gastroenterol. Hepatol.* 13, 1000–8.e3. doi: 10.1016/j.cgh.2014.10.008
- Tacke, F. (2017). Targeting hepatic macrophages to treat liver diseases. *J. Hepatol.* 66, 1300–1312. doi: 10.1016/j.jhep.2017.02.026
- Takahashi, Y., Soejima, Y., and Fukusato, T. (2012). Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *World J. Gastroenterol.* 18, 2300–2308. doi: 10.3748/wjg.v18.i19.2300
- Takaki, A., Kawai, D., and Yamamoto, K. (2014). Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). *Int. J. Mol. Sci.* 15:7352. doi: 10.3390/ijms15057352
- Teufel, A., Itzel, T., Erhart, W., Brosch, M., Wang, X. Y., Kim, Y. O., et al. (2016). Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. *Gastroenterology* 151, 513–525.e0. doi: 10.1053/j.gastro.2016.05.051
- Tilg, H., and Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 52, 1836–1846. doi: 10.1002/hep.24001
- van Koppen, A., Verschuren, L., van den Hoek, A. M., Verheij, J., Morrison, M. C., Li, K., et al. (2018). Uncovering a predictive molecular signature for the onset of NASH-related fibrosis in a translational NASH mouse model. *Cell. Mol. Gastroenterol. Hepatol.* 5, 83–98.e10. doi: 10.1016/j.jcmgh.2017.10.001
- Wettenhall, J. M., and Smyth, G. K. (2004). limmaGUI: A graphical user interface for linear modeling of microarray data. *Bioinformatics* 20, 3705–3706. doi: 10.1093/bioinformatics/bth449
- Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., et al. (2015). Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 148, 547–555. doi: 10.1053/j.gastro.2014.11.039
- Younossi, Z. M., Baranova, A., Ziegler, K., Del Giacco, L., Schlauch, K., Born, T. L., et al. (2005). A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. *Hepatology* 42, 665–674. doi: 10.1002/hep.20838
- Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., and Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 64, 73–84. doi: 10.1002/hep.28431
- Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., et al. (2017). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat. Rev. Gastroenterol. Hepatol.* 15, 11–20. doi: 10.1038/nrgastro.2017.109
- Zhang, Y., Baker, S. S., Baker, R. D., Zhu, R., and Zhu, L. (2012). Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. *PLoS ONE* 7:e51131. doi: 10.1371/journal.pone.0051131
- Zimmer, M., Bista, P., Benson, E. L., Lee, D. Y., Liu, F., Picarella, D., et al. (2017). CAT-2003: a novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. *Hepatol. Commun.* 1, 311–325. doi: 10.1002/hep.4.1042

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Morrison, Kleemann, van Koppen, Hanemaaijer and Verschuren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.